Feline Infectious Peritonitis

Feline Infectious Peritonitis (FIP) is a progressive, immune-mediated, systemic disease of domestic and wild felids caused by a mutant form of feline coronavirus (FCoV) [1]. It is widely regarded as one of the most important infectious causes of death in cats, with young cats under 2 years of age being especially vulnerable, though geriatric cats are also at elevated risk [1]. FIP arises when feline enteric coronavirus (FCoV) — typically a benign gut pathogen — mutates within an individual cat, allowing the virus to replicate within macrophages and disseminate systemically [2]. Historically, FIP carried a near-universally fatal prognosis, but the advent of antiviral nucleoside analog therapy has fundamentally transformed outcomes for affected cats [5][6].

The Causative Agent

FIP is caused by a virulent biotype of feline coronavirus (FCoV), a single-stranded, positive-sense RNA virus belonging to the family Coronaviridae, genus Alphacoronavirus [2]. FCoV is ubiquitous in cat populations, particularly in multi-cat households and catteries, where seroprevalence can reach 80–90% [7]. The virus primarily circulates as feline enteric coronavirus (FCoV type I and II), which replicates in intestinal epithelial cells and is shed in feces, spreading via feco-oral transmission [2].

Mutation and Pathogenesis

The prevailing "internal mutation" hypothesis holds that FIP arises when FCoV mutates — most commonly in genes encoding the spike protein (S gene) or accessory proteins (3c, 7a/b) — within an individual cat's gastrointestinal tract, converting a replication-competent enteric virus into a macrophage-tropic variant [2][4]. The key virulence shift is the acquisition of the ability to efficiently infect and replicate within monocytes and macrophages, enabling systemic dissemination throughout the body via the bloodstream [2][8].

Immune-Mediated Pathology

The resulting pathology is characterized by a perivascular pyogranulomatous or granulomatous phlebitis that can affect virtually any organ [2]. Virus-laden macrophages trigger dysregulated immune responses, including complement activation, cytokine storms (particularly IL-1β, IL-6, TNF-α), and immune complex deposition, leading to severe vasculitis [4]. In the effusive form, increased vascular permeability results in protein-rich effusions in body cavities. In the non-effusive form, granulomatous lesions predominate in parenchymal organs, eyes, and the central nervous system [7][8].

Risk Factors

• ·Young age (< 2 years) and old age (> 10 years) [1]
• ·Purebred cats (particularly Ragdoll, Bengal, Birman, and other breeds with potential genetic susceptibility) [2]
• ·Multi-cat environments, shelters, and catteries with high FCoV prevalence [7]
• ·Immunosuppression (e.g., concurrent FeLV or FIV infection) [7]
• ·Stress (e.g., rehoming, surgery, crowding) [7]
• ·It is estimated that approximately 5–12% of FCoV-infected cats may develop FIP, with stress predisposing to disease progression [7]

Definitive antemortem diagnosis of FIP remains one of the most challenging problems in feline medicine, as no single non-invasive test is pathognomonic [1][8]. A combination of history, signalment, clinical signs, and multi-parameter laboratory evaluation is used to build a diagnostic picture [1].

Hematology and Serum Biochemistry

Key laboratory abnormalities that raise suspicion for FIP include [1][2][8]:

An albumin-to-globulin (A:G) ratio < 0.4 is considered highly supportive of FIP; a ratio > 0.8 makes FIP unlikely [1][8].

Effusion Analysis

In cats with body cavity effusions, fluid analysis is central to diagnosis [1][2]:

• ·Appearance: Viscous, yellow to straw-colored, often clots upon standing
• ·Total protein: > 35 g/L (typically very high)
• ·Rivalta test: Positive (simple, low-cost, high sensitivity ~91%, specificity ~66%)
• ·Cytology: Pyogranulomatous inflammation; predominantly non-degenerate neutrophils and macrophages
• ·Effusion A:G ratio: < 0.4 strongly supportive
• ·FCoV RT-PCR on effusion: High sensitivity in effusive FIP; detection of FCoV RNA in effusion fluid is strongly supportive [8]

Serology

• ·FCoV antibody titers: Detect exposure to FCoV but cannot differentiate FCoV from FIP virus; high titers in the context of clinical disease increase suspicion, but titers may be low or absent in end-stage FIP [4][8]
• ·Seronegative results do not rule out FIP [1]

Acute Phase Proteins

• ·Alpha-1-acid glycoprotein (AGP): Markedly elevated (> 1,500 µg/mL) in FIP; useful as a supportive marker, though non-specific [8]

Molecular and Immunological Testing

• ·RT-PCR for FCoV RNA: Can be performed on blood, effusion, CSF, or tissue; highly sensitive in effusion for wet FIP; sensitivity lower in dry FIP and blood [8]
• ·Immunohistochemistry (IHC): Detection of FCoV antigen within macrophages in tissue biopsies or cytology specimens represents the gold standard for definitive diagnosis [1][2][8]
• ·Immunofluorescence or immunocytochemistry on effusion: Detection of FCoV antigen in macrophages within effusion fluid — a positive result is considered confirmatory [1]
• ·FIP-specific spike gene mutation testing (RT-PCR): Emerging approach detecting mutations in the spike protein gene associated with FIPV biotype, though standardization is ongoing [2]

Imaging

• ·Abdominal ultrasound: Key imaging modality with characteristic findings including free abdominal effusion, hyperechoic or mottled mesenteric fat, mesenteric lymphadenopathy, peritoneal fibrin stranding, and multifocal hypoechoic lesions in liver, spleen, or kidneys [3]
• ·Retroperitoneal effusion and segmental intestinal wall thickening have also been described [3]
• ·Thoracic radiography/ultrasound: Identifies pleural effusion and mediastinal involvement [2]
• ·MRI/CT (neurological FIP): May reveal meningeal enhancement, ventricular dilation, or periventricular lesions [2]

Diagnostic Scoring Systems

The Pedersen criteria and subsequent refinements (e.g., the Feline Internal Medicine scoring approach) integrate multiple parameters (signalment, clinical signs, lab values, effusion characteristics) to derive a probability score for FIP diagnosis prior to histopathology confirmation [1][4][8].

Historically, FIP was considered universally fatal, and treatment was limited to supportive care. The discovery and development of nucleoside analog antivirals has transformed FIP into a potentially curable disease in a substantial proportion of cats [5][6].

Antiviral Therapy

GS-441524 (Nucleoside Analog)

GS-441524 is a nucleoside analog and molecular precursor to a pharmacologically active nucleoside triphosphate that acts as an RNA-chain terminator of the viral RNA-dependent RNA polymerase, thereby inhibiting viral replication [5]. Early experimental studies demonstrated potent in vitro and in vivo efficacy against FIP virus [5]. GS-441524 is now available in multiple formulations (oral tablets, injectable) and has demonstrated high remission rates across all FIP forms [6].

Key clinical evidence:

• ·A retrospective study of 307 cats treated with legally sourced, veterinary-compounded remdesivir (injectable) and GS-441524 (oral tablets) demonstrated that the majority of cats achieved clinical remission with appropriate treatment duration [6]
• ·Treatment protocols generally involve 12 weeks of therapy minimum, with neurological and ocular FIP typically requiring higher doses and longer durations [1][6]
• ·Recommended starting doses vary by form: effusive FIP typically 6–8 mg/kg/day (oral GS-441524); neurological/ocular FIP typically 8–12 mg/kg/day or higher [6]

Remdesivir

Remdesivir (GS-5734), a prodrug of GS-441524, is available as an injectable formulation and has been used particularly in the early/induction phase of treatment, especially in neurological cases or cats unable to tolerate oral medication [6]. Transition to oral GS-441524 is typically made once the cat is stable [6].

Monitoring During Antiviral Treatment

• ·Regular reassessment of clinical signs, body weight, and effusion resolution [1][6]
• ·Serial complete blood count (CBC) and biochemistry: normalization of lymphopenia, anemia, hyperglobulinemia, and hypoalbuminemia serves as a treatment response marker [1]
• ·Effusion should resolve within 1–4 weeks in responsive cases [6]
• ·Treatment duration is typically 84 days (12 weeks) minimum, with neurological/ocular cases often extended to 84+ days; a 12-week observation period off treatment before declaring remission is standard [1][6]

Supportive / Adjunctive Therapy

• ·Corticosteroids (prednisolone 1–2 mg/kg/day): Historically used as the mainstay of supportive care; may still be used short-term in severely ill cats to reduce initial inflammation while antiviral therapy begins, particularly in neurological FIP [2][7]
• ·Therapeutic drainage of effusions: Large-volume thoracocentesis or abdominocentesis to relieve respiratory distress or discomfort; not curative but provides immediate relief [2][7]
• ·Nutritional support: Assisted feeding (syringe feeding, esophagostomy tubes) in anorexic cats to maintain body condition during treatment [1]
• ·Fluid therapy: To correct dehydration and electrolyte imbalances [2]
• ·Anti-emetics, appetite stimulants: Mirtazapine or maropitant as needed [1]

Drugs No Longer Recommended as Primary Treatment

• ·Interferon-omega, polyprenyl immunostimulant, and immunosuppressive protocols with cyclophosphamide were previously investigated but showed limited efficacy compared to antiviral therapy and are no longer considered first-line treatment [4][7]

Historical Prognosis (Pre-Antiviral Era)

Prior to the availability of nucleoside analog antivirals, FIP was considered virtually uniformly fatal, with survival measured in days to weeks for the effusive form and weeks to months for the dry form following diagnosis [4][7]. Supportive care alone rarely prolonged life meaningfully, and euthanasia was the most common outcome.

Current Prognosis With Antiviral Therapy

The availability of GS-441524 and remdesivir has dramatically altered the prognosis for FIP [5][6]:

• ·In the landmark retrospective study of 307 cats treated with legally sourced, veterinary-compounded GS-441524 or remdesivir, a substantial majority of cats achieved clinical remission and survived to complete treatment [6]
• ·Cats with effusive (wet) FIP typically show rapid clinical improvement within 1–2 weeks of initiating antiviral therapy, with effusion resolving in most responsive cases [6]
• ·Cats with neurological or ocular FIP have historically carried a more guarded prognosis and typically require higher drug doses and longer treatment durations; however, meaningful response rates are still achievable with appropriate therapy [1][6]
• ·Approximately 10–40% of cats may relapse after completing the initial 12-week course, requiring retreatment at higher doses or with alternative protocols [6]
• ·Cats that complete a full course of antiviral therapy and survive the 12-week observation period post-treatment are considered to have achieved sustained remission, which appears durable in many cases [6]

Disease Burden

• ·FIP accounts for an estimated 0.3% to 1.4% of feline deaths at veterinary institutions [1]
• ·Approximately 5–12% of FCoV-infected cats are estimated to develop FIP, with stress and immunosuppression as key predisposing factors [7]
• ·Without antiviral treatment, mortality approaches 100% once clinical FIP is established [4][7]

Prognostic Factors

• ·Favorable: Early diagnosis, effusive form without neurological involvement, young adult age, good body condition, owner compliance with full treatment course
• ·Unfavorable: Neurological involvement, severe anemia (HCT < 15%), severe thrombocytopenia (PLT < 50,000/µL), extreme hyperbilirubinemia, marked hypoalbuminemia at presentation, concurrent immunosuppressive disease (FeLV/FIV) [1][6]

Vaccination

• ·A modified-live intranasal FCoV vaccine (Primucell FIP®, Zoetis) targeting the temperature-sensitive DF2 strain has been licensed in some countries [2][7]
• ·The vaccine is administered intranasally to cats ≥ 16 weeks of age and targets induction of local mucosal immunity [7]
• ·Its efficacy is controversial and limited: it provides partial protection in seronegative cats but offers minimal benefit to cats already seropositive for FCoV at the time of vaccination — which is a common situation in endemic multi-cat environments [2][7]
• ·The ABCD guidelines do not recommend universal vaccination but consider it may have some utility in seronegative cats entering high-risk environments [2]

Husbandry and Environmental Management

Reducing FCoV transmission is the cornerstone of prevention in multi-cat settings [2][7]:

• ·Litter box hygiene: FCoV is shed in feces; keeping litter boxes clean (scooping at least once daily, disinfecting weekly) significantly reduces environmental viral load [7]
• ·Litter box to cat ratio: Providing one litter box per cat plus one extra reduces cross-contamination [7]
• ·Quarantine of new cats: New arrivals should be isolated for a minimum of 2–3 weeks before introduction to a resident population [2][7]
• ·FCoV serology screening: Testing new cats before introduction can help identify persistently shedding cats, though seropositive status only indicates exposure [7]
• ·Population density management: Limiting group sizes to fewer than 5 cats in a household or compartmentalizing large catteries into stable groups significantly reduces FCoV seroprevalence and transmission [7]
• ·Early weaning protocols (in catteries): Separating kittens from FCoV-positive queens at weaning (5–6 weeks) before the window of most active FCoV transmission has shown success in producing FCoV-negative litters in research settings, though it is logistically demanding [7]
• ·Stress reduction: Minimizing stressors (rehoming, surgery, overcrowding, concurrent illness) reduces the risk of viral mutation and FIP development in FCoV-seropositive cats [7]
• ·Environmental disinfection: FCoV is susceptible to most household disinfectants including dilute bleach (1:32 dilution), quaternary ammonium compounds, and accelerated hydrogen peroxide; regular surface disinfection is recommended in cattery settings [2][7]

Genetic Considerations

• ·Certain purebred lines appear to have higher susceptibility to FIP, suggesting a genetic component [2]
• ·Responsible breeding programs should monitor FIP incidence and consider selective breeding strategies in high-risk breeds, though specific genetic screening tests are not yet clinically available [2]